Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination of Induction Durvalumab and Tremelimumab Alone Versus Durvalumab and Tremelimumab With Chemotherapy for Potentially Resectable Pleural Mesothelioma

NCT05932199 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT05932199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05932199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination of Induction Durvalumab and Tremelimumab Alone Versus Durvalumab and Tremelimumab With Chemotherapy for Potentially Resectable Pleural Mesothelioma
Lead sponsor
Baylor College of Medicine
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 3, 2024
Completion date
May 31, 2028
Enrollment
52 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

mesothelioma